Extended Data Fig. 10: Combination of molnupiravir or remdesivir with the protease inhibitor PF-07321332 is additive against SARS-CoV-2 (Beta, Delta).
From: Pyrimidine inhibitors synergize with nucleoside analogues to block SARS-CoV-2
BLISS analysis in Calu-3 cells with molnupiravir (EIDD-2801) or remdesivir in combination with PF-07321332 infected with the indicated SARS-CoV-2 variant. Data are presented as mean Excess over BLISS for n = 2 independent biological replicates (SARS-CoV-2 Beta); n = 6 independent biological replicates (SARS-CoV-2 Delta). The statistical significance was determined by a one-sample t-test (* p < 5x10−2; **p < 10−3).
